Cargando…

Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome

BACKGROUND: This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC). METHODS: A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Marcia, Savvatis, Konstantinos, Nixon, Katherine, Kyrgiou, Maria, Hariharan, Kuhan, Padwick, Malcolm, Owens, Owen, Cunnea, Paula, Campbell, Jeremy, Farthing, Alan, Stumpfle, Richard, Vazquez, Ignacio, Watson, Neale, Krell, Jonathan, Gabra, Hani, Rustin, Gordon, Fotopoulou, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682567/
https://www.ncbi.nlm.nih.gov/pubmed/31243666
http://dx.doi.org/10.1245/s10434-019-07516-3
_version_ 1783441909441626112
author Hall, Marcia
Savvatis, Konstantinos
Nixon, Katherine
Kyrgiou, Maria
Hariharan, Kuhan
Padwick, Malcolm
Owens, Owen
Cunnea, Paula
Campbell, Jeremy
Farthing, Alan
Stumpfle, Richard
Vazquez, Ignacio
Watson, Neale
Krell, Jonathan
Gabra, Hani
Rustin, Gordon
Fotopoulou, Christina
author_facet Hall, Marcia
Savvatis, Konstantinos
Nixon, Katherine
Kyrgiou, Maria
Hariharan, Kuhan
Padwick, Malcolm
Owens, Owen
Cunnea, Paula
Campbell, Jeremy
Farthing, Alan
Stumpfle, Richard
Vazquez, Ignacio
Watson, Neale
Krell, Jonathan
Gabra, Hani
Rustin, Gordon
Fotopoulou, Christina
author_sort Hall, Marcia
collection PubMed
description BACKGROUND: This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC). METHODS: A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and December 2014 was performed. The Mayo Clinic surgical complexity score (SCS) was applied. Cox regression analysis identified the impact of treatment methods on survival. RESULTS: The study identified 249 patients (127 at center A and 122 in centre B) without significant differences in International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO 4, 29.7% at centers A and B), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG < 2, 89.9% at centers A and B), or histology (serous type in 84.1% at centers A and B). The patients at center A were more likely to undergo surgery (87% vs 59.8%; p < 0.001). The types of chemotherapy and the patients receiving palliative treatment alone were equivalent between the two centers (3.6%). The median SCS was significantly higher at center A (9 vs 2; p < 0.001) with greater tumor burden (9 vs 6 abdominal fields involved; p < 0.001), longer median operation times (285 vs 155 min; p < 0.001), and longer hospital stays (9 vs 6 days; p < 0.001), but surgical morbidity and mortality were equivalent. The independent predictors of reduced overall survival (OS) were non-serous histology (hazard ratio [HR], 1.6; 95% confidence interval [CI] 1.04–2.61), ECOG higher than 2 (HR, 1.9; 95% CI 1.15–3.13), and palliation alone (HR, 3.43; 95% CI 1.51–7.81). Cytoreduction, of any timing, had an independent protective impact on OS compared with chemotherapy alone (HR, 0.31 for interval surgery and 0.39 for primary surgery), even after adjustment for other prognostic factors. CONCLUSIONS: Incorporating surgery into the initial EOC management, even for those patients with a greater tumor burden and more disseminated disease, may require more complex procedures and more resources in terms of theater time and hospital stay, but seems to be associated with a significant prolongation of the patients overall survival compared with chemotherapy alone.
format Online
Article
Text
id pubmed-6682567
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-66825672019-08-19 Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome Hall, Marcia Savvatis, Konstantinos Nixon, Katherine Kyrgiou, Maria Hariharan, Kuhan Padwick, Malcolm Owens, Owen Cunnea, Paula Campbell, Jeremy Farthing, Alan Stumpfle, Richard Vazquez, Ignacio Watson, Neale Krell, Jonathan Gabra, Hani Rustin, Gordon Fotopoulou, Christina Ann Surg Oncol Gynecologic Oncology BACKGROUND: This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC). METHODS: A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and December 2014 was performed. The Mayo Clinic surgical complexity score (SCS) was applied. Cox regression analysis identified the impact of treatment methods on survival. RESULTS: The study identified 249 patients (127 at center A and 122 in centre B) without significant differences in International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO 4, 29.7% at centers A and B), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG < 2, 89.9% at centers A and B), or histology (serous type in 84.1% at centers A and B). The patients at center A were more likely to undergo surgery (87% vs 59.8%; p < 0.001). The types of chemotherapy and the patients receiving palliative treatment alone were equivalent between the two centers (3.6%). The median SCS was significantly higher at center A (9 vs 2; p < 0.001) with greater tumor burden (9 vs 6 abdominal fields involved; p < 0.001), longer median operation times (285 vs 155 min; p < 0.001), and longer hospital stays (9 vs 6 days; p < 0.001), but surgical morbidity and mortality were equivalent. The independent predictors of reduced overall survival (OS) were non-serous histology (hazard ratio [HR], 1.6; 95% confidence interval [CI] 1.04–2.61), ECOG higher than 2 (HR, 1.9; 95% CI 1.15–3.13), and palliation alone (HR, 3.43; 95% CI 1.51–7.81). Cytoreduction, of any timing, had an independent protective impact on OS compared with chemotherapy alone (HR, 0.31 for interval surgery and 0.39 for primary surgery), even after adjustment for other prognostic factors. CONCLUSIONS: Incorporating surgery into the initial EOC management, even for those patients with a greater tumor burden and more disseminated disease, may require more complex procedures and more resources in terms of theater time and hospital stay, but seems to be associated with a significant prolongation of the patients overall survival compared with chemotherapy alone. Springer International Publishing 2019-06-26 2019 /pmc/articles/PMC6682567/ /pubmed/31243666 http://dx.doi.org/10.1245/s10434-019-07516-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Gynecologic Oncology
Hall, Marcia
Savvatis, Konstantinos
Nixon, Katherine
Kyrgiou, Maria
Hariharan, Kuhan
Padwick, Malcolm
Owens, Owen
Cunnea, Paula
Campbell, Jeremy
Farthing, Alan
Stumpfle, Richard
Vazquez, Ignacio
Watson, Neale
Krell, Jonathan
Gabra, Hani
Rustin, Gordon
Fotopoulou, Christina
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
title Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
title_full Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
title_fullStr Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
title_full_unstemmed Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
title_short Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
title_sort maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome
topic Gynecologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682567/
https://www.ncbi.nlm.nih.gov/pubmed/31243666
http://dx.doi.org/10.1245/s10434-019-07516-3
work_keys_str_mv AT hallmarcia maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT savvatiskonstantinos maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT nixonkatherine maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT kyrgioumaria maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT hariharankuhan maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT padwickmalcolm maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT owensowen maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT cunneapaula maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT campbelljeremy maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT farthingalan maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT stumpflerichard maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT vazquezignacio maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT watsonneale maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT krelljonathan maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT gabrahani maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT rustingordon maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome
AT fotopoulouchristina maximaleffortcytoreductivesurgeryforovariancancerpatientswithahightumorburdenvariationsinpracticeandimpactonoutcome